These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30384039)

  • 1. Prevalence and correlates of thrombosis in adults with immune thrombocytopenia: An NIS study.
    Machin N; Ragni MV; Comer DM; Yabes JG
    Thromb Res; 2018 Dec; 172():80-85. PubMed ID: 30384039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antiphospholipid antibodies and the risk of thrombosis: a comparative survey between chronic immune thrombocytopenia and primary antiphospholipid syndrome].
    Moulis G; Delavigne K; Huguet F; Fortenfant F; Beyne-Rauzy O; Adoue D
    Rev Med Interne; 2011 Dec; 32(12):724-9. PubMed ID: 21864953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presence of Antiphospholipid Antibodies as a Risk Factor for Thrombotic Events in Patients with Connective Tissue Diseases and Idiopathic Thrombocytopenic Purpura.
    Habe K; Wada H; Matsumoto T; Ohishi K; Ikejiri M; Matsubara K; Morioka T; Kamimoto Y; Ikeda T; Katayama N; Mizutani H
    Intern Med; 2016; 55(6):589-95. PubMed ID: 26984073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relevance of antiphospholipid antibody profile in the clinical outcome of ITP: a single-centre study.
    Frison L; Lombardi A; Caputo I; Semenzato G; Fabris F; Vianello F
    Hematology; 2019 Dec; 24(1):134-138. PubMed ID: 30355275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifocal avascular necrosis in a patient with refractory immune thrombocytopenia and antiphospholipid antibodies; case report and review of literature.
    El-Gendy H; El-Gohary RM; Mahfouz S; Ahmed HMA; El Demerdash DM; Ragab G
    Platelets; 2019; 30(5):664-671. PubMed ID: 30373491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of immune thrombocytopenic purpura associated with the antiphospholipid antibody syndrome.
    Leuzzi RA; Davis GH; Cowchock FS; Murphy S; Vernick JJ
    Clin Exp Rheumatol; 1997; 15(2):197-200. PubMed ID: 9196875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics, risk factors and management of venous thromboembolism in immune thrombocytopenia: a retrospective multicentre study.
    Le Guenno G; Guieze R; Audia S; Khellaf M; Michel M; Bonnotte B; Ruivard M; Godeau B
    Intern Med J; 2019 Sep; 49(9):1154-1162. PubMed ID: 30816621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors.
    Ruggeri M; Tosetto A; Palandri F; Polverelli N; Mazzucconi MG; Santoro C; Gaidano G; Lunghi M; Zaja F; De Stefano V; Sartori R; Fazi P; Rodeghiero F;
    J Thromb Haemost; 2014 Aug; 12(8):1266-73. PubMed ID: 24942752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammatory Bowel Disease and Thrombosis: A National Inpatient Sample Study.
    Cohen JB; Comer DM; Yabes JG; Ragni MV
    TH Open; 2020 Jan; 4(1):e51-e58. PubMed ID: 32435723
    [No Abstract]   [Full Text] [Related]  

  • 10. High prevalence of anti-prothrombin antibody in patients with deep vein thrombosis.
    Ishikura K; Wada H; Kamikura Y; Hattori K; Fukuzawa T; Yamada N; Nakamura M; Nobori T; Nakano T
    Am J Hematol; 2004 Aug; 76(4):338-42. PubMed ID: 15282665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of thrombotic events in patients with immune thrombocytopenia.
    Ito S; Fujiwara SI; Ikeda T; Toda Y; Mashima K; Umino K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Ann Hematol; 2020 Jan; 99(1):49-55. PubMed ID: 31853702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: A systematic review and meta-analysis.
    Moulis G; Audemard-Verger A; Arnaud L; Luxembourger C; Montastruc F; Gaman AM; Svenungsson E; Ruggeri M; Mahévas M; Gerfaud-Valentin M; Brainsky A; Michel M; Godeau B; Lapeyre-Mestre M; Sailler L
    Autoimmun Rev; 2016 Mar; 15(3):203-9. PubMed ID: 26708169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of thrombopoeitin mimetics for refractory immune thrombocytopenia purpura in patients with systemic lupus erythematosus or antiphospholipid syndrome: a case series.
    Lusa A; Carlson A
    Lupus; 2018 Sep; 27(10):1723-1728. PubMed ID: 29673280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immune thrombocytopenia paradox: Should we be concerned about thrombosis in ITP?
    Saldanha A; Colella MP; Villaça PR; Thachil J; Orsi FA
    Thromb Res; 2024 Sep; 241():109109. PubMed ID: 39137700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiphospholipid antibodies in adults with immune thrombocytopenic purpura.
    Pierrot-Deseilligny Despujol C; Michel M; Khellaf M; Gouault M; Intrator L; Bierling P; Godeau B
    Br J Haematol; 2008 Aug; 142(4):638-43. PubMed ID: 18510681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cerebral venous thrombosis and immune thrombocytopenia in a 7-year-old girl: a fortuitous association?].
    Cotillon M; Lebas A; Blanc T; Schneider P; Vannier JP; Buchbinder N
    Arch Pediatr; 2014 Dec; 21(12):1367-9. PubMed ID: 25445130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombosis in immune thrombocytopenia - current status and future perspectives.
    Swan D; Newland A; Rodeghiero F; Thachil J
    Br J Haematol; 2021 Sep; 194(5):822-834. PubMed ID: 33822358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune thrombocytopenia increases the risk of thrombosis: A two-sample Mendelian randomization study.
    Yu J; Fu L; Jin G; Gao F; Ding L; Hong L; Lv S; Jin J; Tang L; Feng W; Zhang K; Xu C
    Int J Cardiol; 2024 Nov; 414():132417. PubMed ID: 39098611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Thrombocytopenic Purpura as a Hemorrhagic Versus Thrombotic Disease: An Updated Insight into Pathophysiological Mechanisms.
    Tărniceriu CC; Hurjui LL; Florea ID; Hurjui I; Gradinaru I; Tanase DM; Delianu C; Haisan A; Lozneanu L
    Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus.
    Maroun MC; Ososki R; Andersen JC; Dhar JP
    Lupus; 2015 Jun; 24(7):746-50. PubMed ID: 25416695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.